Abstract 931P
Background
Currently, there is a paucity of validated deep learning methodologies for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma (NPC), both domestically and internationally. Furthermore, advanced techniques such as 2.5D feature extraction and Transformer model establishment remain underexplored in this context.
Methods
MRI images from locally advanced NPC patients diagnosed at two centers between July 2020 and June 2023 were retrospectively collected. Three state-of-the-art (SOTA) models (SegResNet, Unet, and UnetR models) were employed for automatic segmentation of all regions of interest (ROIs), thus generating an automatic segmentation model. Leveraging 2.5D deep learning techniques, tumor image features were extracted and integrated into a transfer learning framework. Subsequently, a Transformer-based model was designed, integrating all individual patient features. Three models were established: a clinical model, a Transformer model, and a fusion model. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the three models, the Transformer model demonstrated superior predictive performance in both the testing (AUC = 0.957) and validation cohorts (AUC = 0.893) compared to the clinical model. Moreover, the fusion model generally matched or surpassed the performance of the Transformer model, particularly in the testing cohort with an AUC of 0.874, indicating that the integration of clinical data with advanced machine learning models can enhance predictive capability.
Conclusions
The fusion model, which combines machine learning with clinical factors, exhibits promising efficacy in predicting short-term outcomes in locally advanced NPC patients following synchronous chemoradiotherapy.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1056P - Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records
Presenter: Annelies Verbiest
Session: Poster session 03
1057P - Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysis
Presenter: Simeone D'Ambrosio
Session: Poster session 03
1058P - Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
Presenter: Damien Bruyat
Session: Poster session 03
1059P - Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers
Presenter: Rebecca Romanò
Session: Poster session 03
1060P - Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learning
Presenter: Song-Bin Guo
Session: Poster session 03
1061P - Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic review
Presenter: Filippo Vitale
Session: Poster session 03
1062P - Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy
Presenter: Èlia Sais
Session: Poster session 03
1063P - Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 03